Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients

BACKGROUND: Enzyme replacement therapy is currently the only approved therapy for Fabry disease. From June 2009 on, viral contamination of Genzyme's production facility resulted in a worldwide shortage of agalsidase beta leading to involuntary dose reductions (approved dose 1 mg/kg/eow, reduced...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Smid, Bouwien E, Rombach, Saskia M, Aerts, Johannes MFG, Kuiper, Symen, Mirzaian, Mina, Overkleeft, Hermen S, Poorthuis, Ben JHM, Hollak, Carla EM, Groener, Johanna EM, Linthorst, Gabor E
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2011
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3219561/
https://ncbi.nlm.nih.gov/pubmed/22041095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1750-1172-6-69
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky